jayempi
nova laboratories ireland limited - azathioprine - zavrnitev presadka - imunosupresivi - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.
qaialdo
nova laboratories ireland limited - spironolakton - edema; heart failure; liver cirrhosis; ascites; nephrotic syndrome; hyperaldosteronism; essential hypertension - antihypertensives and diuretics in combination - in the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension. neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5. 1 in 5.
aldactone 25 mg obložene tablete
riemser pharma gmbh - spironolakton - obložena tableta - spironolakton 25 mg / 1 tableta - spironolakton
aldactone 50 mg obložene tablete
riemser pharma gmbh - spironolakton - obložena tableta - spironolakton 50 mg / 1 tableta - spironolakton
aldactone 100 mg trde kapsule
riemser pharma gmbh - spironolakton - kapsula, trda - spironolakton 100 mg / 1 kapsula - spironolakton
ampril hd 5 mg/25 mg tablete
krka, d.d., novo mesto - hidroklorotiazid; ramipril - tableta - hidroklorotiazid 25 mg / 1 tableta ramipril5 mg / 1 tableta; ramipril 5 mg / 1 tableta - ramipril in diuretiki
ampril hl 2,5 mg/12,5 mg tablete
krka, d.d., novo mesto - hidroklorotiazid; ramipril - tableta - hidroklorotiazid 12,5 mg / 1 tableta ramipril2,5 mg / 1 tableta; ramipril 2,5 mg / 1 tableta - ramipril in diuretiki
azafalk 75 mg filmsko obložene tablete
dr. falk pharma gmbh - azatioprin - filmsko obložena tableta - azatioprin 75 mg / 1 tableta - azatioprin
metoject 50 mg/ml raztopina za injiciranje v napolnjeni injekcijski brizgi
medac gmbh - metotreksat - raztopina za injiciranje v napolnjeni injekcijski brizgi - metotreksat 50 mg / 1 ml - metotreksat
metoject 50 mg/ml raztopina za injiciranje v napolnjeni injekcijski brizgi
medac gmbh - metotreksat - raztopina za injiciranje v napolnjeni injekcijski brizgi - metotreksat 50 mg / 1 ml - metotreksat